Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India

Cytokine release syndrome (CRS) or cytokine storm is thought to be the cause of inflammatory lung damage, worsening pneumonia and death in patients with COVID-19. Steroids (Methylprednislone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dravid, Ameet, Kashiva, Reema, Khan, Zafer, Memon, Danish, Kodre, Aparna, Potdar, Prashant, Mane, Milind, Borse, Rakesh, Pawar, Vishal, Patil, Dattatraya, Banerjee, Debashis, Bhoite, Kailas, Pharande, Reshma, Kalyani, Suraj, Raut, Prathamesh, Bapte, Madhura, Mehta, Anshul, Reddy, M. Sateesh, Bhayani, Krushnadas, Laxmi, S. S., Vishnu, P. D., Srivastava, Shipra, Khandelwal, Shubham, More, Sailee, Shinde, Rohit, Pawar, Mohit, Harshe, Amol, Kadam, Sagar, Mahajan, Uma, Joshi, Gaurav, Mane, Dilip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294888/
https://www.ncbi.nlm.nih.gov/pubmed/34398044
http://dx.doi.org/10.1097/MD.0000000000026705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294888/
https://www.ncbi.nlm.nih.gov/pubmed/34398044
http://dx.doi.org/10.1097/MD.0000000000026705

Ejemplares similares